Feider Stephen 4/A

What Happened

• Stephen Feider, Chief Financial Officer of Beta Bionics, reported a grant/award of 110,342 derivative shares on a Form 4. The acquisition price is reported as $0.00 (i.e., a grant/award rather than a cash purchase). This filing is an amendment reporting the transaction dated 2026-02-27.

Key Details

• Transaction date: 2026-02-27 (Amended Form 4 filed 2026-03-13).
• Transaction type/code: Grant/Award (code A); derivative securities (not an open-market purchase or sale).
• Shares involved: 110,342 shares reported as acquired at $0.00.
• Vesting: Footnote F1 — the shares/options vest in 36 equal monthly installments measured from March 1, 2026.
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: This is an amended filing made 14 days after the transaction date; it appears to be filed late relative to the usual 2-business-day Form 4 reporting requirement.

Context

• This was a grant/award of derivative securities (likely options or restricted units) that vest over time — not an immediate market purchase or sale. Such awards are common as compensation and do not by themselves indicate an insider buying or selling shares on the open market. The amendment and filing delay are procedural items investors may note when tracking insider activity.